Figure 8.

Fluorescence intensity analysis and fluorescence imaging of AlPcS₄ in SGC-7901 cells after treatment with AlPcS₄ + 5-FU, AlPcS₄ + DOX, AlPcS₄ + MMC, AlPcS₄ + CDDP, AlPcS₄ + VCR and free-AlPcS₄. (A-E) Fluorescent intensity analysis of AlPcS₄ in SGC-7901 cells after treatment with 1–32 µm/ml free-AlPcS₄, AlPcS₄ + 5-FU (20 µm), AlPcS₄ + DOX (0.4 µm), AlPcS₄ + MMC (0.5 µm/ml), AlPcS₄ + CDDP (5 µm) or AlPcS₄ + VCR (0.1 µm/ml) for 6 h and measured by using a fluorescence spectrophotometer. The data represents the average of three experiments and the bar is the SD. *P<0.05 and **P<0.01 represented a statistically significant difference in the fluorescence intensity of AlPcS₄ in cells between the combination therapy of AlPcS₄ with a chemical agent and single therapy of free-AlPcS₄. (F) The fluorescent images of AlPcS₄ in SGC-7901 cells after treatment with 32 µm/ml free-AlPcS₄, AlPcS₄ + 5-FU (20 µm), AlPcS₄ + DOX (0.4 µm/ml), AlPcS₄ + MMC (0.5 µm/ml), AlPcS₄ + CDDP (5 µm) or AlPcS₄ + VCR (0.1 µm/ml) for 6 h and measured using a fluorescence microscope. All the images were acquired at an ×400 magnification. The scale bar represented 20 µm. AlPcS₄, Al(III) phthalocyanine chloride tetrasulfonic acid; 5-FU, 5-fluorouracil; DOX, doxorubicin; CDDP, cisplatin; MMC, mitomycin C; VCR, vincristine.